Select Page

How Structurally Similar is SARS-CoV-2 to SARS?

Apr 9, 2020 | Blog | 0 comments

Daniel Gigante

Brett Averso (CTO, EVQLV) shows and explains the undeniable structural similarities between SARS-CoV-2 and SARS. We hope this video serves to dispel some of the myths you may have encountered during your search for answers surrounding coronavirus.

It should be noted that despite the similarities this does not mean antibodies used to treat SARS can be effectively leveraged to treat COVID-19. This is explained in our previous video.

0 Comments

Submit a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

by | May 13, 2022 | Blog, News | 0 Comments

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

Read More

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

by | June 29, 2021 | Press Releases | 0 Comments

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (Issuewire.com)  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...
Read More

NY Bio-Computation Startup EVQLV Closes Financing Round

by | February 8, 2021 | Press Releases | 0 Comments

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...
Read More

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

by | February 1, 2021 | News | 0 Comments

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...
Read More

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

by | January 12, 2021 | Press Releases | 0 Comments

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...
Read More